-
公开(公告)号：US20180273620A1
公开(公告)日：2018-09-27
申请号：US15743756
申请日：2016-07-15
Applicant: UCB Biopharma SPRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Kerry Louise TYSON , Michael John WRIGHT
IPC: C07K16/28
Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
42.发明授权公开(公告)号：US10039826B2
公开(公告)日：2018-08-07
申请号：US15549528
申请日：2016-02-05
Applicant: UCB Biopharma SPRL
Inventor： Michael Joseph Edouard Boonen , Claude Peerboom
IPC: A61K39/395 , C07K16/28 , A61K47/18 , A61K47/26 , A61K47/12
Abstract: The current invention relates to a new pharmaceutical formulation, in particular to a pharmaceutical formulation comprising a protein, more particularly an antibody as an active ingredient.
-
公开(公告)号：USD819804S1
公开(公告)日：2018-06-05
申请号：US29602184
申请日：2017-04-28
Applicant: UCB Biopharma SPRL
Designer： Barry Alan Knight , Marko Plevnik , Norihiko Inoue , Jamie Buckley , Lisa Hornsey
-
公开(公告)号：US09988446B2
公开(公告)日：2018-06-05
申请号：US14690892
申请日：2015-04-20
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Terence Seward Baker , Alastair David Griffiths Lawson
IPC: A61K39/395 , C07K16/24
CPC classification number: C07K16/244 , C07K2317/33 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：US09988383B2
公开(公告)日：2018-06-05
申请号：US15100697
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D473/00 , C07D473/32 , A61K31/5377
CPC classification number: C07D473/00 , A61K31/5377 , C07D473/32
Abstract: A series of substituted purine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
Patent Agency Ranking
公开(公告)号：USD816834S1
公开(公告)日：2018-05-01
申请号：US29602191
申请日：2017-04-28
Applicant: UCB Biopharma SPRL
Designer： Barry Alan Knight , Marko Plevnik , Norihiko Inoue , Jamie Buckley , Lisa Hornsey
-
公开(公告)号：US09956274B2
公开(公告)日：2018-05-01
申请号：US14991048
申请日：2016-01-08
Applicant: UCB Biopharma SPRL
Inventor： Terence Seward Baker
IPC: C12N5/07 , A61K39/395 , A61K39/00 , A61K38/12 , C07K16/00 , C07K14/705 , C07K16/28
CPC classification number: A61K39/0005 , A61K2039/545 , A61K2039/6081 , A61K2039/62 , C07K14/705 , C07K16/28 , C07K2317/14 , C07K2317/20 , C07K2317/76
Abstract: The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.
-
公开(公告)号：US09932342B2
公开(公告)日：2018-04-03
申请号：US15100690
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Mezher Hussein Ali , Daniel Christopher Brookings , Julien Alistair Brown , Victoria Elizabeth Jackson , Boris Kroeplien , John Robert Porter
IPC: C07D487/04 , A61K31/519 , A61K31/5377
CPC classification number: C07D487/04 , A61K31/519 , A61K31/5377
Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09902768B2
公开(公告)日：2018-02-27
申请号：US14380310
申请日：2013-02-22
Applicant: UCB Pharma S.A.
Inventor： David Paul Humphreys , Shirley Jane Peters
CPC classification number: C07K16/24 , C07K16/00 , C07K16/468 , C07K2317/31 , C07K2317/51 , C07K2317/522 , C07K2317/53 , C07K2317/55 , C07K2317/94
Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterized in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.
-
公开(公告)号：US09902720B2
公开(公告)日：2018-02-27
申请号：US15038766
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/5377
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/5377
Abstract: A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
-
-
-
-
-
-
-
-
Search Results
175
records
(took 0.056 seconds)
